TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer [TH versus THL]

Trial Profile

TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer [TH versus THL]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TH v THL
  • Most Recent Events

    • 20 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 14 Mar 2012 New source identified and integrated (EudraCT2011-005189-39; European Clinical Trials Database).
    • 07 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top